Recent News

• 08.06.2026 - Biogen Completes Acquisition of RayThera Inc.
• 07.15.2026 - Biogen Appoints Michael J. Parini as Chief Legal Officer
• 07.14.2026 - LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
• 07.14.2026 - Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
• 07.13.2026 - FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
• 07.12.2026 - LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
• 06.29.2026 - Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
• 06.17.2026 - Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.
• 06.04.2026 - Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
• 06.04.2026 - EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus

Recent Filings

• 08.06.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.04.2026 - 144 Report of proposed sale of securities
• 08.03.2026 - 144 Report of proposed sale of securities
• 07.29.2026 - 8-K Current report
• 07.29.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.29.2026 - EX-99.1 EX-99.1
• 07.01.2026 - 8-K Current report
• 06.11.2026 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2026 - 4 Statement of changes in beneficial ownership of securities